Publicacións en colaboración con investigadores/as de Fundación Hospital Alcorcón (39)

2024

  1. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

    Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8

  2. Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study

    Journal of Nutrition, Health and Aging, Vol. 28, Núm. 8

  3. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

    European urology oncology, Vol. 7, Núm. 3, pp. 447-455

  4. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789

2023

  1. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e166-e174

  2. Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study

    PLoS ONE, Vol. 18, Núm. 5 May

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

  3. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer

  4. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer, Vol. 167, pp. 142-148

  5. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

    Gut, Vol. 72, Núm. 2, pp. 345-359

  6. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)

    Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 635-645

  7. Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study

    European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346

2021

  1. Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol

    PLoS ONE, Vol. 15, Núm. 12 December

  2. Breast cancer patient experiences through a journey map: A qualitative study

    PLoS ONE, Vol. 16, Núm. 9 September

  3. Electronic health records and patient registries in medical oncology departments in Spain

    Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108

  4. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  5. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  6. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

    Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936

  7. Trajectories of alcohol consumption during life and the risk of developing breast cancer

    British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176